Brief Values Intervention for Veterans in Early Buprenorphine Treatment

This study is testing a brief, values-based intervention to help Veterans who are starting medication treatment for opioid use disorder (OUD). This intervention, which involves four weekly sessions, aims to improve your social connections and quality of life during early recovery. You may be able to join if you are a Veteran diagnosed with moderate to severe OUD and have started buprenorphine, methadone, or naltrexone treatment within the last 12 weeks (or up to 12 months for a later phase of the study). Researchers will look at how satisfied participants are and how well the intervention is received to see if a larger study is needed. The study's current status is unclear, and it plans to enroll 50 participants.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It is designed in three phases, with a planned enrollment of 50 participants.
What's involved
Participants will take part in four weekly sessions as part of the intervention. Researchers will measure your responses at 1 week and 6 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your satisfaction will be measured at 6 weeks, and recruitment will be tracked through study completion, up to three years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05189223

A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment

Recruiting
NAAges 18+InterventionalTreatment
VA Office of Research and Development
~50 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:Brief, values based intervention for early buprenorphine treatment

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Expectancy item of the Credibility/Expectancy Questionnaire (CEQ)
Measured over 1 week
+5 more outcomes measured
Dependence, Opioid
1 sites across 1 states
Massachusetts1
  • Victoria Ameral, PhD · PRINCIPAL_INVESTIGATOR · VA Bedford HealthCare System, Bedford, MA

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Meets current Diagnostic and Statistical Manual - 5th Edition criteria for moderate to severe opioid use disorder
Phase 2: Within 12 weeks of initiating buprenorphine, methadone, or naltrexone treatment for opioid use disorder following at least 2 months without treatment; Phase 3: Within 12 weeks of initiating buprenorphine, methadone, or naltrexone treatment for opioid use disorder following at least 2 months without treatment
Competent to provide written informed consent

Exclusion

Evidence of active psychosis or mania
Suicidality requiring inpatient hospitalization
Active substance use requiring detoxification
Cognitive impairment that would interfere with study participation
  • Expectancy item of the Credibility/Expectancy Questionnaire (CEQ)1 week

    The Credibility/Expectancy Questionnaire (CEQ) is a 6-item self-report measure which will be administered following the first intervention session. Expectancy will be measured using item 4, the most common index for expectancy. This item is rated on a scale from 0% to 100% with higher percentages reflecting higher anticipated improvement. As an indicator of acceptability of the intervention in Phase 3, the investigators will use a priori benchmark of average expectancy at or above 50%. improvement expected.

  • Number of participants recruitedThrough study completion, up to three years

    Feasibility will be assessed in Phase 3 using an a priori benchmark of at least n=2 participants recruited on average per month.

  • Client Satisfaction Questionnaire 8-item (CSQ-8)6 weeks

    The Client Satisfaction Questionnaire 8-item (CSQ-8) is a commonly used 8-item measure which has been used with similar participant samples to assess treatment satisfaction. Scores range from 8 to 32, with higher scores reflecting higher satisfaction. It will be used in Phase 3 as an additional measure of acceptability for the intervention, using an a priori benchmark of average satisfaction scores at or above 24.

  • Number of treatment sessions attended6 weeks

    Feasibility will be assessed in Phase 3 using an a priori benchmark of at least 3 of the 4 sessions attended by 50% or more of the study participants. The six week time frame provides some flexibility for scheduling the 4 weekly study sessions.

  • Therapist Adherence6 weeks

    Therapist adherence and competence scales will be developed in Phase 2 and used to assess Therapist Adherence to the treatment as a feasibility measure using an a priori benchmark of 80%. The scale will be adapted from a rating system designed to assess use of broadly defined ACT-consistent therapeutic strategies, appropriate use of specific ACT techniques from a given manual, and the absence of techniques that are inconsistent with ACT-based interventions. The structure of the overall scale will be retained, such that each item is assessed for frequency and extensiveness on a scale of 1 (not at all) to 5 (extensively).

  • Credibility subscale of the Credibility/Expectancy Questionnaire (CEQ)1 Week

    The Credibility/Expectancy Questionnaire (CEQ) is a 6-item self-report measure which will be administered following the first intervention session. The three item Credibility subscale produces scores ranging from 3 to 27, with higher scores reflecting higher credibility. As an indicator of acceptability of the intervention in Phase 3, the investigators will use an a priori benchmark of average credibility at or above 15, reflecting a "somewhat" credible rating.